// App-Quantinova.ai

PB1805 : ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA

Researchers

Presenter

  • Kevin H.M. Kuo

Principal Investigators

  • D. Mark Layton

  • Hanny Al-Samkari

  • Antonis Kattamis

  • Sujit Sheth

  • Ali Taher

  • Vip Viprakasit

  • Christina X. Chamberlain

  • Lauren Czapla

  • Sarah Gheuens

  • Liewen Jiang

  • Megan Lynch

  • Bo Tong

  • Katrin Uhlig

  • M. Domenica Cappellini

Medical Centers

  • AGIOS Pharmaceuticals Inc,Cambridge,United States

  • St Marys Hospital, Imperial CollegeHealthcare NHS Trust, London, UK

  • University of Milan, Milan, Italy

  • Weill Cornell Medical College, New York City, NY, United States

  • Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

  • First Department of Radiology, Aretaieion Hospital, National and Kapodistrian University of Athens, Athens, Greece

  • Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, United States

  • American University of Beirut (AUB), Beirut, Lebanon

  • Division of Dermatology, University of Toronto, Toronto,Canada

Locations

  • United States

  • United Kingdom

  • Italy

  • Thailand

  • Greece

  • Lebanon

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Ophthalmology (OP)

  • Blood/haematological Diseases

Disease

  • Beta-thalassemia

  • Non‐transfusion‐dependent β‐thalassaemia

Biomarkers

  • Red Blood Cells

  • Tumor doubling time

Drug/Treatment

  • Energize Liquid

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved